132 related articles for article (PubMed ID: 37804754)
21. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
22. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Chen LC; Chen TC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
[TBL] [Abstract][Full Text] [Related]
23. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
Sant M; Minicozzi P; Mounier M; Anderson LA; Brenner H; Holleczek B; Marcos-Gragera R; Maynadié M; Monnereau A; Osca-Gelis G; Visser O; De Angelis R;
Lancet Oncol; 2014 Aug; 15(9):931-42. PubMed ID: 25030467
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
Ghannam J; Dillon LW; Hourigan CS
Br J Haematol; 2020 Jan; 188(1):77-85. PubMed ID: 31804716
[TBL] [Abstract][Full Text] [Related]
25. Application of precision medicine in clinical routine in haematology-Challenges and opportunities.
Wästerlid T; Cavelier L; Haferlach C; Konopleva M; Fröhling S; Östling P; Bullinger L; Fioretos T; Smedby KE
J Intern Med; 2022 Aug; 292(2):243-261. PubMed ID: 35599019
[TBL] [Abstract][Full Text] [Related]
26. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
27. [Retrospective analysis of chronic myeloid leukemia patients treated in the Department of Internal Medicine and Oncology, Semmelweis University, between 2003 and 2019].
Weisinger J; Tárkányi I; Hanna E; Kárpáti Á; Nagy Z; Timár B; Csomor J; Kiss R; Gángó A; Bödör C; Demeter J
Orv Hetil; 2021 Aug; 162(32):1297-1302. PubMed ID: 34370689
[TBL] [Abstract][Full Text] [Related]
28. [Practical management of side effects of tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
Mezei G; Illés Á; Batár P
Orv Hetil; 2021 Jul; 162(30):1198-1207. PubMed ID: 34304154
[TBL] [Abstract][Full Text] [Related]
29. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
Kittai A; Yu EM; Tabbara I
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25538217
[TBL] [Abstract][Full Text] [Related]
30. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.
Murai K; Ureshino H; Kumagai T; Tanaka H; Nishiwaki K; Wakita S; Inokuchi K; Fukushima T; Yoshida C; Uoshima N; Kiguchi T; Mita M; Aoki J; Kimura S; Karimata K; Usuki K; Shimono J; Chinen Y; Kuroda J; Matsuda Y; Nakao K; Ono T; Fujimaki K; Shibayama H; Mizumoto C; Takeoka T; Io K; Kondo T; Miura M; Minami Y; Ikezoe T; Imagawa J; Takamori A; Kawaguchi A; Sakamoto J; Kimura S
Lancet Haematol; 2021 Dec; 8(12):e902-e911. PubMed ID: 34826413
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
32. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study.
Merin D; Krishna A; Jayakumar S; Mahima A; Anila KN; Sidharthan N
J Oncol Pharm Pract; 2023 Apr; 29(3):547-556. PubMed ID: 35048760
[TBL] [Abstract][Full Text] [Related]
34. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
Liu WM; Stimson LA; Joel SP
Br J Cancer; 2002 May; 86(9):1472-8. PubMed ID: 11986783
[TBL] [Abstract][Full Text] [Related]
35. Detection of BCR-ABL fusion gene and its transcript variants in chronic myeloid leukaemia patients - a multi-comparison study.
Javed A; Mukhtar H; Kubra KT; Lodhi S; Abaidullah S
J Pak Med Assoc; 2020 Oct; 70(10):1748-11752. PubMed ID: 33159746
[TBL] [Abstract][Full Text] [Related]
36. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Rotta I; Fernandez-Llimos F; Pontarolo R
Br J Clin Pharmacol; 2019 Oct; 85(10):2280-2291. PubMed ID: 30907446
[TBL] [Abstract][Full Text] [Related]
37. 'If I don't work, I don't get paid': An Australian qualitative exploration of the financial impacts of acute myeloid leukaemia.
Parker C; Berkovic D; Wei A; Zomer E; Liew D; Ayton D
Health Soc Care Community; 2022 Sep; 30(5):e2069-e2079. PubMed ID: 34766671
[TBL] [Abstract][Full Text] [Related]
38. The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.
Guilhot F; Coombs J; Szczudlo T; Zernovak O; Paolantonio M; Bender C; Macdonald NJ; Shapiro A
Patient; 2013; 6(2):81-92. PubMed ID: 23529848
[TBL] [Abstract][Full Text] [Related]
39. Chronic myeloid leukaemia accelerates proliferative retinopathy in patients with co-existent diabetes: A risk factor not to be ignored.
Chawla R; Kumar S; Kumawat D; Azad SV; Temkar S; Jain S
Eur J Ophthalmol; 2021 Jan; 31(1):226-233. PubMed ID: 31514533
[TBL] [Abstract][Full Text] [Related]
40. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
